CLAIMS:

1.   (Previously presented) A method of affecting new neuron growth in a patient comprising the step of:

administering to a patient in need thereof a therapeutic amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors for increasing levels of cGMP to a patient in need of neurogenesis post stroke wherein increased levels of cGMP result in new neuron growth.

Please cancel claims 2-5.

6.   (Previously presented) A method of augmenting the production of neurons in a patient by administering to a patient in need thereof an effective amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors that increases levels of cGMP, to a site in need of augmentation, wherein increased levels of cGMP augment the production of new neurons.

7.   (Previously presented) A method of increasing neurological function in a patient by administering to a patient in need thereof an effective amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors that increases levels of cGMP to a patient in need of increased neurological function after neurological damage has occurred, whereby the increased levels of cGMP create new neuron growth, thereby increasing neurological function.

8.   (Previously presented) A method of increasing cognitive and neurological function in a patient by administering an effective amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors for increasing levels of cGMP to a patient in need of increased cognitive and neurological function after neurological and cognitive

damage has occurred, whereby the increased levels of cGMP create new neuron growth, thereby increasing neurological function.

Please cancel claims 9-13.